use
sinc
ancient
time
especi
local
treatment
pulmonari
diseas
lung
airway
versatil
target
rout
administr
local
system
drug
despit
exist
differ
platform
devic
pulmonari
administr
drug
formul
market
partli
due
physiolog
technolog
limit
respiratori
infect
repres
signific
burden
health
system
worldwid
mainli
due
intrahospit
infect
easili
affect
immunecompromis
patient
moreov
tuberculosi
tb
endem
infecti
diseas
mani
develop
nation
resurg
develop
world
associ
human
immunodefici
virusacquir
immunodefici
syndrom
hivaid
epidem
current
medicin
face
specter
antibiot
resist
besid
develop
new
antiinfecti
drug
develop
innov
effici
deliveri
system
drug
went
patent
appear
promis
strategi
pursu
pharmaceut
industri
improv
therapeut
outcom
prolong
util
intellectu
properti
portfolio
context
nanotechnologybas
drug
deliveri
system
nanodd
emerg
promis
approach
circumv
limit
convent
formul
treat
drug
resist
open
hypothesi
new
develop
area
macrophag
inhal
compound
mean
treat
diseas
use
sinc
ancient
time
oldest
report
came
china
india
around
bc
relat
inhal
smoke
burn
herbal
prepar
base
ephedra
sinica
daturastramonium
treat
asthma
respect
pedanu
discorid
greek
physician
surgeon
pharmacologist
botanist
author
de
materia
medica
consid
first
pharmacopeia
well
aeliu
galenu
ad
prescrib
inhal
sulfur
vapor
patient
although
word
inhal
use
first
time
english
physician
john
mudg
describ
invent
first
therapeut
inhal
devic
attribut
hippocr
bc
year
mani
compound
mixtur
propos
use
treat
differ
diseas
use
variou
method
inhal
ceram
inhal
combust
powder
burn
paper
liquid
atom
curiou
popular
way
inhal
compound
centuri
asthma
cigarett
withdrawn
market
inhal
vapor
solut
picric
acid
tar
iodin
sulfur
acid
popular
centuri
treat
tb
infect
especi
spa
first
mention
regard
inhal
antibiot
penicillin
nebul
treat
pulmonari
infect
publish
nowaday
inhal
drug
preferenti
administ
via
dri
powder
inhal
dpi
pressur
metereddos
inhal
pmdi
also
use
nebul
hospit
despit
inhal
start
rout
treat
diseas
constrain
respiratori
tract
scientif
technolog
advanc
chang
paradigm
took
place
year
inhal
clinic
evalu
use
treat
local
system
diseas
asthma
tb
bacteri
infect
influenza
viru
infect
fungal
infect
cystic
fibrosi
chronic
obstruct
pulmonari
diseas
diabet
cancer
moreov
inhal
also
test
noninvas
vaccin
platform
driven
progress
nanomedicin
field
mani
research
develop
innov
formul
improv
biopharmaceut
featur
allow
pulmonari
administr
mani
drug
otherwis
could
administ
inhal
formul
repres
promis
although
preliminari
altern
convent
inhal
formul
context
new
door
open
field
inhal
therapi
new
advanc
could
expect
near
futur
work
review
stateofon
overcom
drug
resist
lung
airway
site
ga
exchang
contact
exterior
expos
organ
inorgan
biolog
compon
caus
diseas
varieti
bacteri
viral
fungal
parasit
infect
affect
lung
progress
toward
system
infect
includ
pneumonia
tb
influenza
aspergillosi
among
other
infect
lower
respiratori
tract
among
top
three
major
caus
morbid
worldwid
first
lowincom
countri
respons
approxim
million
death
annual
pneumonia
common
infecti
pulmonari
diseas
mani
etiolog
agent
includ
bacteria
virus
fungi
streptococcu
pneumonia
haemophilu
influenza
type
b
acinetobact
baumannii
klebsiella
pneumonia
moraxella
catarrhali
human
respiratori
syncyti
viru
human
parainfluenza
viru
mycoplasma
pneumonia
chlamydophila
pneumonia
legionella
pneumophila
pneumocysti
jiroveci
lead
caus
death
children
worldwid
kill
annual
around
million
children
age
five
year
nosocomi
pneumonia
especi
ventil
patient
unfortun
frequent
repres
antibiot
prescript
intens
care
unit
also
develop
resist
strain
hospit
caus
great
deal
concern
among
health
profession
therapi
chosen
accord
etiolog
agent
sever
diseas
reason
imper
identifi
etiolog
agent
sensit
avail
therapeut
portfolio
order
treat
patient
ration
way
prevent
develop
resist
strain
tb
infecti
diseas
caus
bacillu
mycobacterium
tuberculosi
primarili
exclus
affect
lung
second
lead
caus
death
infecti
diseas
worldwid
declar
global
public
health
emerg
world
health
organ
distinct
never
grant
diseas
around
million
incid
case
tb
million
death
among
hivneg
peopl
addit
million
death
hivassoci
tb
current
therapi
includ
longterm
multipl
dose
oral
administr
variou
drug
sometim
lead
low
patient
complianc
therefor
develop
multidrugresist
strain
refer
multidrug
resist
tb
mdrtb
extens
drugresist
tb
xdrtb
firstlin
drug
use
treatment
standard
tb
rifampicin
isoniazid
pyrazinamid
ethambutol
streptomycin
moment
new
drug
clinic
trial
constitut
hope
treatment
resist
form
diseas
addit
develop
resist
difficulti
treat
tb
stem
fact
administ
system
mani
antitb
drug
fail
reach
lung
penetr
alveolar
macrophag
reservoir
tuberculosi
tuberculosi
persist
macrophag
within
granuloma
form
lung
infect
host
thu
tradit
drug
chemotherapi
seriou
limit
particularli
drug
intern
cytosol
avail
infect
phagocyt
cell
phenomenon
driven
mani
research
develop
drug
deliveri
system
dd
improv
treatment
burden
anoth
import
question
relat
incid
pulmonari
fungal
infect
increas
last
decad
partial
due
grow
number
immunecompromis
patient
relat
hiv
cancer
hematolog
disord
organ
transplant
varieti
fungal
infect
histoplasmosi
histoplasma
capsulatum
sporotrichosi
sporothrix
schenkii
blastomycosi
blastomyc
dermatitidi
coccidioidomycosi
coccidioid
spp
paracoccidioidomycosi
paracoccidioid
brasiliensi
cryptococcosi
cryptococcu
spp
aspergillosi
aspergillu
spp
candidiasi
candida
spp
pneumonia
candida
spp
pneumocysti
spp
trichosporon
spp
infect
caus
pulmonari
injuri
differ
sever
actual
varieti
antifung
drug
avail
market
gener
administ
oral
intraven
includ
amphotericin
b
deoxychol
amb
itraconazol
voriconazol
caspofungin
among
antifung
drug
use
treat
fungal
infect
amb
consid
gold
standard
therapi
commonli
use
therapi
treat
lifethreaten
case
nephroand
cardiotox
amb
major
clinic
drawback
could
lead
treatment
discontinu
moment
market
formul
amb
usual
use
clinic
practic
eg
gilead
scienc
bristolmy
squibb
enzon
pharmaceut
inc
lipidbas
dd
present
lower
toxic
result
higher
drug
therapeut
index
amb
extens
formul
variou
nanodd
proofofconcept
use
nanomedicin
deliveri
antifung
drug
regard
viral
infect
anoth
devast
problem
sever
virus
respons
acut
respiratori
infect
name
influenza
viru
coxsacki
viru
echoviru
adenoviru
respiratori
syncyti
viru
rhinoviru
parainfluenza
viru
corona
viru
recent
human
metapneumoviru
torqu
tenoviru
human
bocaviru
polyomavirus
avian
influenza
viru
polyomaviru
nevertheless
influenza
viru
main
caus
viral
airway
infect
worldwid
relat
sever
annual
epidem
respiratori
syncyti
viru
parainfluenza
viru
import
caus
viral
infect
lower
respiratori
tract
children
vaccin
primari
mean
prevent
control
viral
infect
especi
annual
outbreak
influenza
moment
drug
avail
treat
pulmonari
viral
infect
like
amantadin
endo
pharmaceut
inc
rimantadin
forest
pharmaceut
inc
oseltamivir
hoffmannla
roch
usual
use
young
elderli
group
patient
seriou
medic
condit
current
drug
administ
oral
rout
recent
zanamivir
formul
dpi
glaxosmithklin
approv
treatment
influenza
pulmonari
rout
unfortun
yet
specif
treatment
vaccin
avail
virus
identifi
recent
sinc
antimicrobi
agent
reduc
ill
death
associ
infect
discoveri
penicillin
one
greatest
advanc
health
centuri
howev
year
accumul
overus
misus
antiinfecti
drug
led
develop
resist
strain
microorgan
develop
genet
mutat
acquisit
resist
gene
defens
mechan
make
danger
difficult
treat
methicillinresist
staphylococcu
aureu
vancomycinresist
enterococcu
result
prolong
ill
greater
risk
death
addit
intracellular
infect
difficult
erad
due
low
avail
activ
antiinfecti
drug
insid
cell
order
treat
patient
resist
strain
high
dose
drug
use
present
advers
effect
healthi
tissu
organ
despit
advanc
seen
develop
new
antibiot
drug
resist
remain
huge
public
health
problem
accord
world
health
organ
around
new
case
mdrtb
emerg
annual
caus
least
death
worldwid
case
drug
resist
also
report
hiv
influenza
nowaday
main
research
focu
infecti
diseas
fall
develop
strategi
improv
therapeut
index
avail
drug
nanotechnolog
forefront
research
pharmacokinet
pharmacodynam
drug
highli
depend
physic
chemic
featur
influenc
type
formul
use
deliv
scale
size
compound
nanodd
modul
improv
perform
mani
drug
extent
achiev
convent
formul
exampl
nanodd
capit
encapsul
drug
therebi
increas
solubl
ii
protect
degrad
iii
enhanc
epitheli
absorpt
increas
blood
circul
time
iv
target
drug
specif
cellstissuesorgan
releas
control
manner
respons
specif
stimulu
v
enhanc
uptak
cell
addit
combin
nanodd
simultan
detect
treat
diseas
encompass
imag
therapeut
compound
emerg
field
known
theranost
near
futur
nanomedicin
could
play
key
role
achiev
highli
desir
person
medicin
last
decad
use
design
develop
nanodd
overcom
varieti
biopharmaceut
drawback
diagnosi
prevent
immun
treatment
diseas
intens
explor
larg
number
research
group
worldwid
lead
great
number
scientif
articl
publish
intern
journal
moreov
gener
profus
intellectu
properti
platform
howev
despit
fact
nanomedicin
began
disciplin
almost
half
centuri
ago
nanodd
found
way
market
phenomenon
could
explain
lack
financi
profit
consum
distrust
lack
confid
due
poor
informationeduc
ineffect
regul
new
gener
product
weak
patent
protect
moment
regulatori
agenc
process
develop
specif
guidelin
regul
regard
nanotechnologybas
product
order
develop
new
tool
standard
approach
assess
safeti
efficaci
qualiti
perform
product
nonetheless
rel
market
nanodd
success
respect
therapeut
area
accord
bcc
research
global
nanomedicin
market
grow
steadili
reach
valu
billion
anticanc
agent
market
leader
expect
increas
annual
growth
rate
reach
billion
context
mani
research
group
consolid
concept
pulmonari
deliveri
drug
use
nanodd
preliminari
result
promis
expect
clinic
relev
product
could
proven
clinic
trial
therapeut
effici
antiinfecti
drug
improv
enhanc
solubl
pulmonari
accumul
intracellular
deliveri
thu
increas
local
concentr
drug
reduc
dose
frequenc
administr
minim
time
drug
system
side
effect
consequ
patient
complianc
augment
avoid
develop
multidrugresist
strain
still
sever
issu
larg
scale
product
batchtobatch
reproduc
variabl
lung
deposit
pattern
costeffect
balanc
treatment
need
address
optim
order
ensur
benchtobedsid
translat
inhalatori
nanodd
state
inhal
serv
platform
deliveri
drug
aim
display
local
system
activ
anatom
physiolog
characterist
make
airway
suscept
infect
extern
pathogen
exploit
drug
deliveri
respiratori
system
provid
noninvas
rout
deliveri
larg
surfac
area
thin
epitheli
barrier
extens
blood
suppli
blood
flow
lower
enzymat
activ
compar
organ
bodi
eg
liver
gastrointestin
tract
also
firstpass
metabol
avoid
pulmonari
administr
especi
use
drug
suffer
high
hepat
metabol
inhal
particl
transport
inhal
air
respiratori
tract
deposit
exhal
among
featur
influenc
behavior
inhal
particl
airway
mean
aerodynam
diamet
eq
play
import
role
govern
particl
deposit
pattern
deq
diamet
equival
volum
sphere
unit
densiti
particl
unit
densiti
x
dynam
shape
factor
commonli
accept
optim
mean
aerodynam
diamet
rang
particl
deposit
lower
airway
particl
larger
undergo
deposit
oropharynx
consequ
swallow
particl
smaller
like
exhal
howev
studi
area
environment
toxicolog
show
nanoparticl
size
rang
nm
could
also
randomli
deposit
great
extent
lower
airway
fig
mechan
involv
particl
deposit
also
depend
anatomi
airway
region
includ
inerti
impact
sediment
diffus
fig
besid
drug
pharmaceut
excipi
constitut
integr
part
pharmaceut
formul
provid
physic
chemic
microbiolog
stabil
bulk
properti
improv
handl
meter
control
mechan
pharmaceut
properti
formul
releas
permeat
moment
small
number
excipi
author
pulmonari
deliveri
varieti
new
excipi
evalu
sinc
lung
limit
buffer
capac
compound
biocompat
endogen
lung
easili
metabol
clear
use
inhal
formul
sinc
formul
nebul
liquid
solut
suspens
common
excipi
use
salt
eg
nacl
adjust
osmolar
mosmol
hcl
naoh
phosphat
adjust
ph
neutral
surfact
polysorb
sorbitan
monostear
oleic
acid
soy
lecithin
facilit
format
liquid
droplet
ethanol
use
cosolv
permeat
enhanc
small
concentr
due
irrit
potenti
preserv
antioxid
chelat
agent
paraben
benzalkonium
chlorid
ascorb
acid
ethylenediaminetetraacet
acid
edta
also
use
enhanc
stabil
excipi
use
pmdi
similar
found
prepar
nebul
except
ga
propel
wide
excipi
use
propel
pmdi
hydrofluoroalkan
nontox
nonflamm
chemic
stabl
ga
without
carcinogen
mutagen
effect
due
absenc
ozonedeplet
properti
hydrofluoroalkan
replac
chlorofluorocarbonbas
propel
dpi
develop
respons
limit
regard
stabil
environment
aspect
pmdi
nebul
solid
dispers
drug
blend
coars
carrier
particl
efficaci
dpi
depend
powder
technolog
particl
engin
dpi
coars
carrier
particl
major
compon
formul
ww
provid
bulk
properti
reduc
cohes
forc
drug
particl
facilit
aerosol
dispers
defin
deposit
pattern
lactos
main
excipi
use
coars
larger
carrier
particl
lower
extent
cryoprotect
particl
prepar
use
lyophil
varieti
inhal
grade
lactos
narrow
particl
size
distribut
like
lactohal
inhalac
respitos
commerci
avail
sugar
glucos
trehalos
mannitol
also
use
cryoprotect
coars
carrier
magnesium
stearat
approv
inhal
protect
drug
moistur
reduc
cohes
adhes
particl
regard
inhal
nanodd
compon
gener
approv
inhal
case
new
excipi
propos
inhalatori
formul
need
pass
entir
process
safeti
evalu
includ
complet
vitro
toxicolog
evalu
vivo
assess
nonclin
clinic
safeti
prior
licens
unfortun
lack
specif
regulatori
guidanc
regard
toxicolog
assess
excipi
inhal
excipi
gener
recogn
safe
gra
approv
rout
administr
need
limit
number
experi
safeti
evalu
accept
regulatori
agenc
usual
easier
case
phosphatidylcholin
pc
lipid
surfact
one
constitu
lung
surfact
commonli
use
product
liposom
studi
show
pcbase
liposom
affect
slightli
decreas
viabil
human
alveolar
cell
h
exposur
effect
cell
viabil
depend
pc
deriv
concentr
use
compound
use
develop
nanodd
dextran
algin
carrageenan
gelatin
also
possess
gra
statu
mention
regul
appli
materi
also
sourc
thu
chitosan
obtain
aspergillu
niger
process
obtain
gra
statu
chitosan
present
signific
toxic
pulmonari
tissu
cell
inhal
fact
studi
show
protect
effect
oxid
stress
poli
lactidecoglycolid
plga
anoth
biodegrad
polym
extens
use
product
nanodd
cytotox
plga
nanoparticl
differ
coat
surfac
charg
assess
result
show
cytotox
human
bronchial
cell
limit
absenc
inflammatori
respons
cyclodextrin
cd
test
complex
agent
excipi
inhalatori
formul
variou
approv
formul
contain
cd
novarti
edol
chiesi
farmaceutici
pfizer
use
daili
clinic
practic
administr
rout
inhal
recent
carrierfre
formul
present
good
aerosol
properti
deposit
pattern
develop
propos
promis
inhalatori
formul
carrierless
strategi
avoid
need
long
expens
safeti
studi
facilit
author
regulatori
agenc
moment
commerci
avail
carrierfre
dpi
compos
agglomer
pure
terbutalin
budesonid
particl
name
bricanyl
astrazeneca
pulmicort
astrazeneca
respect
apart
characterist
particl
formul
inhalatori
administr
demand
inhal
devic
produc
appropri
aerosol
numer
devic
avail
distinct
properti
specif
appropri
other
type
formul
fig
sinc
devic
greatli
influenc
particl
aerosol
deposit
pattern
choic
appropri
devic
specif
formul
one
timeconsum
challeng
stage
develop
phase
imper
ensur
drug
efficaci
exampl
alexand
et
al
test
aerosol
efficaci
gilead
scienc
use
differ
nebul
found
differ
among
inhal
devic
need
accur
small
easi
handl
discreet
user
friendli
order
accept
clinician
patient
one
claim
reason
market
failur
pfizer
low
patient
complianc
partli
due
complex
inhal
devic
owe
great
therapeut
potenti
altern
administr
rout
last
decad
wit
develop
devic
greater
pulmonari
deposit
fraction
approxim
nomin
dose
compar
low
level
verifi
past
howev
worth
mention
grow
dynam
field
innov
technolog
emerg
exampl
powerassist
devic
activ
vibrat
pneumat
technolog
call
activ
inhal
develop
deliveri
system
activ
drug
narrow
therapeut
window
inhalatori
nanodd
also
develop
adjust
inhal
present
specif
inhal
pattern
use
treatment
certain
pulmonari
diseas
given
attent
also
import
consid
cost
devic
impact
final
product
price
balanc
pricetherapeut
efficaci
relationship
crucial
factor
limit
clinic
applic
certain
product
sever
infect
frequent
induc
resist
strain
andor
intracellular
pathogen
thu
make
treatment
complex
bacteri
pathogen
tuberculosi
mycobacterium
avium
mycobacterium
intracellular
legionella
pneumophila
respons
differ
pulmonari
diseas
present
capac
overcom
cellular
defens
mechan
infect
cell
often
phagocyt
one
turn
reservoir
convent
antiinfecti
drug
display
drawback
limit
effect
time
erad
intracellular
pathogen
fig
also
drug
display
limit
bioavail
target
microorgan
exert
therapeut
effect
framework
nanodd
could
overcom
limit
improv
therapeut
index
clinic
relev
drug
liposom
amikacin
kanamycin
streptomycin
gentamicin
vancomycin
teicoplanin
present
enhanc
vitro
andor
vivo
efficaci
reduc
viabl
bacteria
count
mycobacterium
aviummycobacterium
intracellular
complex
mac
tuberculosi
klebsiella
pneumonia
methicillinresist
aureu
mrsa
nevertheless
case
pulmonari
biodistribut
differ
drug
low
absent
due
poor
lung
target
accumul
properti
formul
could
overcom
develop
particl
target
lung
eg
nexstar
pharmaceut
inc
local
deliveri
inhal
due
membranelik
structur
liposom
fuse
microorgan
membran
deliv
high
drug
cargo
cytoplasm
satur
drug
efflux
pump
hand
micel
poloxam
present
capac
inhibit
efflux
system
nanoparticl
adsorb
microorgan
surfac
serv
depot
encapsul
drug
taken
infect
cell
increas
avail
antiinfecti
drug
overcom
drug
resist
also
possibl
target
nanoparticl
surfac
receptor
microorgan
improv
therapeut
efficaci
eg
lectindecor
nanoparticl
mani
inhal
antiinfecti
drug
formul
microparticl
system
prove
use
inhal
effect
rout
administr
treat
infecti
diseas
inhal
rifampicinload
plga
microspher
effici
reduc
pulmonari
burden
tuberculosi
present
lower
toxic
compar
free
drug
also
ofloxacinload
hyaluronan
microspher
administ
intratrach
effici
deliv
lung
underw
greater
uptak
alveolar
macrophag
intratrach
ofloxacin
solut
iv
oral
ofloxacinhyaluronan
microspher
proofofconcept
studi
inhal
nanodd
treat
lung
system
infect
report
sever
research
group
tabl
howev
mention
properti
encapsul
drug
pharmaceut
excipi
one
hand
condit
product
aerosol
process
hand
greatli
affect
perform
final
formul
thu
comparison
extrapol
data
differ
studi
difficult
exampl
distearoylphosphatidylcholin
dspc
cholesterol
liposom
intend
inhal
prepar
use
condit
effici
encapsul
isoniazid
pyrazinamid
ethionamid
encapsul
rifampicin
streptomycin
convers
anoth
studi
rifampicin
effici
incorpor
dspccholesterol
liposom
use
similar
prepar
protocol
due
low
water
solubl
rifampicin
focu
studi
regard
encapsul
differ
nanocarri
poli
ethylen
oxid
bdistearoylphosphatidylethanolamin
mpegdsp
micel
propos
carrier
rifampicin
although
therapeut
efficaci
assess
rifampicin
entrap
high
encapsul
effici
micel
sustain
releas
day
vitro
formul
present
fraction
fine
particl
approxim
nebul
accept
valu
increas
system
optim
anoth
studi
liposom
dpi
develop
assess
platform
rifampicin
inhal
cryoprotect
use
freezedri
process
influenc
aerosol
properti
formul
trehalos
mannitol
lactos
mannitol
present
best
result
regard
fine
particl
fraction
mean
aerodynam
diamet
coat
liposom
mucoadhes
polym
chitosan
improv
encapsul
effici
rifampicin
distinctli
affect
nebul
properti
formul
well
cytotox
intim
associ
composit
nevertheless
fine
tune
liposom
composit
consid
mucoadhes
system
enhanc
expect
lung
accumul
rifampicin
thu
therapeut
effect
would
increas
make
promis
strategi
improv
therapeut
index
inhal
rifampicin
aim
avoid
administr
multipl
medicin
daili
basi
zahoor
et
al
develop
alginatechitosan
np
load
simultan
isoniazid
rifampicin
pyrazinamid
around
nebul
formul
present
mean
aerodynam
diamet
suitabl
inhal
biodistribut
studi
perform
guinea
pig
show
presenc
drug
plasma
period
exceed
day
drug
detect
lung
liver
spleen
concentr
minimum
inhibitori
concentr
mic
day
fig
contrast
free
drug
administ
rout
clear
h
addit
inhal
nanoparticl
regimen
one
administr
everi
tabl
furthermor
evid
biochem
hepatotox
similar
result
obtain
group
use
sln
plga
wheat
germ
agglutininplga
nanoparticl
contain
rifampicin
isoniazid
pyrazinamid
though
formul
requir
higher
plasma
resid
time
differ
dose
regimen
exist
receptor
lectin
alveolar
epithelium
could
potenti
absorpt
drug
encapsul
lectinfunction
nanoparticl
modifi
system
emerg
promis
approach
would
allow
reduct
dose
frequenc
improv
patient
complianc
time
costbenefit
balanc
thoroughli
assess
one
ensur
patient
afford
nanodd
load
kanamycin
isoniazid
pyrazinamid
streptomycin
rifampicin
ethionamid
develop
howev
aerosol
properti
therapeut
efficaci
tb
assess
state
nosocomi
respiratori
infect
challeng
current
avail
therapi
repres
seriou
problem
healthcar
unit
encapsul
antibacteri
drug
pulmonari
administr
improv
therapeut
index
lead
reduct
dose
requir
reach
local
mic
liposom
dpi
ciprofloxacin
present
mean
aerodynam
diamet
fine
particl
fraction
appear
possibl
formul
treatment
respiratori
infect
inhalatori
rout
similar
result
obtain
desai
et
al
use
liposom
load
ciprofloxacin
peptid
antimicrobi
properti
anoth
studi
inhal
ciprofloxacinliposom
provid
protect
lethal
pulmonari
tularemia
murin
model
unlik
untreat
control
free
inhal
ciprofloxacin
treat
mice
one
singl
dose
liposom
formul
result
least
surviv
day
inhal
liposom
tobramycin
therapeut
effect
convent
inhalatori
formul
pathogenesi
canada
ltee
pseudomona
aeruginosa
multipl
cyclodextrin
complex
aspergillu
fumigatu
nebul
dose
treatment
conduct
infect
rat
find
explain
differ
pulmonari
pharmacokinet
profil
differ
formul
liposom
display
greater
area
curv
hlung
elimin
halflif
time
h
respect
convent
formul
hlung
h
similar
result
obtain
treatment
rat
infect
burkholderia
cepacia
use
formul
anoth
studi
inhal
liposom
polymyxin
b
present
higher
pulmonari
level
drug
lung
compar
free
drug
lung
reduc
lung
injuri
result
p
aeruginosa
infect
rat
formul
shown
possess
lower
mic
valu
variou
gramneg
bacteria
includ
resist
strain
p
aeruginosa
also
silvercarben
complex
antimicrobi
properti
encapsul
ltyrosin
polyphosph
nanoparticl
nebul
mice
infect
p
aeruginosa
treatment
reduc
number
bacteria
lung
spleen
increas
surviv
anim
recent
stearic
acidgraft
chitosan
oligosaccharid
sacso
micel
develop
pulmonari
administr
amb
ambload
micel
present
antifung
activ
lower
toxic
formul
effici
nebul
use
airjet
nebul
present
fine
particl
fraction
also
treatment
fungal
infect
itraconazol
polysorb
poloxam
nanostructur
aggreg
administ
inhal
mice
present
higher
lung
concentr
lungtoserum
ratio
improv
surviv
infect
anim
lower
toxic
oral
administ
itraconazol
formul
day
studi
sign
lung
inflamm
chang
pulmonari
histolog
detect
worth
stress
lower
drug
dose
requir
achiev
lung
serum
therapeut
level
use
inhal
formul
compar
oral
administr
itraconazol
nanostructur
aggreg
compos
mannitol
lecithin
prepar
ultrarapid
freez
techniqu
also
present
promis
featur
aerosol
suitabl
deep
lung
deliveri
high
lung
deposit
system
absorpt
make
promis
approach
treat
invas
fungal
infect
studi
assess
encapsul
newer
antifung
agent
eg
voriconazolesulfoalkyl
ethercd
complex
treat
pulmonari
fungal
infect
inhal
patent
nebul
complex
produc
fine
particl
fraction
nebul
droplet
apart
enhanc
aqueou
solubl
voriconazol
formul
led
pronounc
increas
accumul
lung
limit
clearanc
plasma
phenomena
increas
therapeut
efficaci
aspergillu
fumigatusinfect
anim
greater
surviv
extent
reduc
lung
damag
observ
cd
propos
carrier
nanodd
also
therapeut
agent
treatment
pulmonari
infect
due
structur
n
boclornithinyl
amino
display
capac
bind
addit
vitro
result
show
prevent
alphahemolysininduc
lysi
human
alveolar
epitheli
cell
cd
prevent
mortal
aureu
pneumonia
murin
model
howev
compound
administ
intraven
necessari
perform
pulmonari
administr
determin
feasibl
inhalatori
therapeut
agent
firstlin
defens
mechan
microorgan
enter
lung
via
airway
consequ
reservoir
mani
pathogen
alveolar
macrophag
drawn
special
attent
relev
clinic
target
variou
nanodd
differ
drug
develop
select
deliv
therapeut
cargo
alveolar
macrophag
present
posit
result
treatment
fungal
bacteri
infect
target
drug
macrophag
could
achiev
tailor
physicochem
properti
carrier
like
size
hydrophil
composit
surfac
charg
surfac
ligand
differ
ligand
galactomannan
context
vya
khatri
publish
interest
review
regard
use
liposom
deliveri
system
alveolar
macrophag
poli
bpoli
ethyleneglycol
bpoli
micel
chitosan
nanoparticl
function
hydrolyz
galactomannan
taken
murin
macrophag
promot
increas
intracellular
level
rifampicin
higher
extent
nonfunction
particl
rifampicinload
liposom
produc
pressur
formul
effici
aerosol
deposit
lower
airway
encapsul
rifampicin
led
reduct
mycobacterium
smegmati
viabil
insid
macrophag
free
drug
phosphatidylcholin
cholesterol
dicetylphosph
pc
chol
dcp
liposom
respect
fig
effect
increas
anchor
mbsa
osap
surfac
liposom
author
specul
ideal
viabil
could
reach
repeat
dose
regimen
taken
macrophag
ligandmodifi
liposom
accumul
lung
prolong
time
clear
slowli
blood
stream
suggest
vivo
biodistribut
studi
wistar
rat
exert
effect
local
effici
approach
appear
feasibl
strategi
treatment
pulmonari
tb
passiv
target
alveolar
macrophag
also
possibl
although
expect
function
liposom
present
better
result
taken
select
cellular
reservoir
bacillu
thu
rifampicinload
phosphatidylcholin
cholesterol
pc
chol
liposom
stabl
presenc
mucu
underw
deposit
lower
airway
administ
rat
importantli
vitro
studi
show
liposom
enhanc
uptak
rifampicin
alveolar
macrophag
inhibit
growth
intracellular
mycobacterium
avium
even
lower
dose
rifampicin
use
rifampicinload
plga
nanoparticl
also
result
higher
uptak
vitro
vivo
alveolar
macrophag
compar
microspher
similar
composit
indic
size
particl
influenc
cellular
uptak
pulmonari
administr
antibacteri
activ
ciprofloxacinload
liposom
intracellular
bacteria
also
assess
uptak
ciprofloxacin
alveolar
macrophag
pulmonari
accumul
inhal
higher
liposom
formul
drug
solut
effect
greater
pammodifi
liposom
antibacteri
activ
variou
intracellular
bacteria
chlamydophila
pneumonia
legionella
pneumophila
listeria
monocytogen
francisella
tularensi
estim
pharmacokineticpharmacodynam
analys
higher
use
liposom
system
enabl
signific
reduct
administ
dose
yet
efficaci
studi
use
pathogen
need
perform
support
result
regard
fungal
infect
opm
opp
use
ligand
recogniz
mannos
receptor
target
ambload
phosphatidylcholin
cholesterol
pc
chol
liposom
alveolar
macrophag
pc
cholmolar
ratio
present
best
relationship
amb
encapsul
effici
hemolysisrel
toxic
howev
increas
percentag
cholesterol
liposom
led
decreas
encapsul
effici
toxic
pmdi
prepar
formul
show
accept
percentag
particl
deposit
lower
airway
vitro
although
smaller
free
drug
solut
addit
administr
rat
liposom
accumul
effect
lung
prolong
releas
respect
free
drug
presenc
opm
opp
improv
pulmonari
accumul
amb
show
better
result
opmanchor
liposom
fig
efficaci
studi
regard
formul
need
evalu
anoth
relev
discoveri
relat
tuftsin
tetrapeptid
thrlysproarg
specif
bind
macrophag
potenti
phagocytosi
immunogen
respons
bactericid
activ
besid
antimicrobi
activ
graft
tuftsin
surfac
liposom
provid
use
deliveri
system
mani
drug
treat
among
infect
tb
leishmaniasi
aspergillosi
still
pulmonari
administr
formul
need
assess
inhal
drug
treat
local
system
patholog
gain
much
attent
last
decad
anatomophysiolog
characterist
respiratori
system
make
promis
noninvas
administr
rout
minim
system
exposur
advers
effect
howev
despit
advantag
present
administr
rout
inhal
requir
formul
fine
tune
properti
eg
aerodynam
properti
well
implement
special
deliveri
devic
make
develop
product
industri
setup
mani
time
difficult
expens
explain
small
number
inhalatori
formul
avail
market
nonetheless
scientif
develop
field
drug
deliveri
inhal
devic
technolog
last
year
increas
interest
pulmonari
deliveri
drug
one
main
develop
field
nanotechnolog
multitud
nanodd
develop
test
main
advantag
abovement
dd
includ
sustain
releas
drug
longer
period
time
prevent
prematur
drug
degrad
improv
drug
absorpt
enhanc
tissu
penetr
accumul
reduct
drug
toxic
regard
antiinfecti
drug
achiev
therapeut
index
use
fewer
drug
dose
well
lower
dose
frequenc
definit
advantag
sinc
improv
patient
complianc
adher
treatment
addit
target
system
alveolar
macrophag
improv
bactericid
activ
intracellular
pathogen
overcom
limit
convent
formul
therefor
inhalatori
nanodd
repres
promis
approach
hope
treatment
respiratori
infect
especi
valuabl
fight
intrahospit
multidrug
resist
strain
although
result
obtain
far
preliminari
steadi
increas
develop
system
proof
therapeut
relev
preclin
model
clinic
trial
could
certainli
envisag
near
futur
